TerminatedPhase 4NCT04707625

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Wake Forest University Health Sciences
Principal Investigator
Mark Nelson, MD
Wake Forest University Health Sciences
Intervention
Aflibercept Ophthalmic(drug)
Enrollment
17 enrolled
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04707625 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials